N-乙酰半胱氨酸治疗慢性肺炎的临床研究  

Efficiency of Oral N-acetylcyeteine for Chronic Pneumonia

作　　者：黄华萍[1] 刘峰[1] 陈明净[2] 王杰[1] 刘美花[1] 陈家亮[1] 李羲[1] 

机构地区：[1]海南医学院第一附属医院呼吸内科海南医学院呼吸病研究所,海口570102 [2]海南医学院第一附属医院病理科,海口570102

出　　处：《中华肺部疾病杂志（电子版）》2017年第3期267-270,共4页Chinese Journal of Lung Diseases(Electronic Edition)

基　　金：国家自然科学基金资助项目(81360001);海南省卫生厅基金课题(琼卫2012PT-24)

摘　　要：目的观察N-乙酰半胱氨酸(NAC)对慢性肺炎患者的临床疗效与安全性,探索药物治疗慢性肺炎的新途径。方法 2012年1月至2015年12月于海南医学院第一附属医院门诊诊断慢性肺炎患者54例,随机分为NAC 0.6 g/d组(n=11例)、NAC 1.2 g/d组(n=13例)、NAC 1.8 g/d组(n=15例)和对照组(n=15例),每4周随访一次,疗程24周。按时间点检测四组患者血常规、肝肾功能、Sp O2和胸部CT。结果 NAC 1.2 g/d组和NAC 1.8 g/d组能够显著改善慢性肺炎患者的胸部CT评分,与对照组比较,差异有统计学意义(P<0.01)。NAC 1.8 g/d组和NAC 1.2 g/d组两组间进行比较,差异无统计学意义(P=0.42)。结论 NAC治疗慢性肺炎有效。NAC的推荐剂量为1 200 mg/d或1 800 mg/d,疗程24周。Objective To investigate the clinical effect of N-acetylcyeteine in patients with chronic pneumonia, and explore a new approach of treatment to chronic pneumonia. Methods A total of 54 patients with chronic pneumonia were recruited into this study from the First Affiliated Hospital of Hainan Medical University between January 2012 and December 2015, and randomly divided into the following four groups： group A （ n = 11 ） received N-acetylcyeteine 0.6 g a day, group B （ n = 13 ） received N-acetylcyeteine 1.2 g a day, group C（n= 15） received N-acetylcyeteine 1.8 g a day and group D（n= 15） received without medication （control group ）. The patients were monitored monthly for 24 weeks. A complete blood count, blood chemistries, SpO2 and chest CT were recorded before and after therapy. In addition, chest CT was performed at week 4 and week 12. Results In comparation with the contrast group or group A, group B or group C could effectively decrease CT scores in patients with chronic pneumonia （P〈0.05）. But there was no significant difference between group B and group C（P=0.42）. Conclusion Oral N-acetylcysteine can be used in chronic pneumonia. Recommended dosage of N-acetylcysteine in patients with chronic pneumonia is 1.2 g or 1.8 g a day for 24 week.

关 键 词：慢性肺炎 N-乙酰半胱氨酸 临床疗效 临床研究 

分 类 号：R563[医药卫生—呼吸系统]